Denmark’s Novo Nordisk has cut its annual revenue and profit forecasts after disappointingly “flabby” sales of its weight loss drug Wegovy, as US prescriptions tailed off.
A boom in sales of Wegovy and the diabetes medication Ozempic helped to turn the drugmaker into Europe’s most valuable listed company, worth $615bn (£461bn) at its peak last year.